Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:7664
Name endometrial mixed adenocarcinoma
Definition An endometrial adenocarcinoma that is composed of both type I (endometrioid) and type II (serous or clear cell type) tumors, with at least 10% of each component.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer endometrial cancer endometrial carcinoma endometrial adenocarcinoma endometrial mixed adenocarcinoma


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA N345K Copanlisib endometrial mixed adenocarcinoma no benefit detail...
PIK3CA H1047X Copanlisib endometrial mixed adenocarcinoma no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03914612 Phase III Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting USA | CAN 3
NCT04196257 Phase I BP1001-A BP1001-A + Paclitaxel BP1001-A in Patients With Advanced or Recurrent Solid Tumors Recruiting USA 0
NCT04197219 Phase II Axitinib + Pembrolizumab Pembrolizumab With Axitinib in Recurrent Endometrial Cancer Withdrawn 0
NCT04750941 Phase II Copanlisib Study of Copanlisib and Ketogenic Diet Active, not recruiting USA 0
NCT05542407 Phase I Atezolizumab + ONC201 ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer Recruiting USA 0
NCT05603910 Phase I Lenvatinib + Pembrolizumab Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma Recruiting USA 0
NCT05826015 Phase I AVB-S6-500 AVB-S6-500 + Paclitaxel AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer Not yet recruiting USA 0